 OUTLINE: This is a multicenter study. Patients are stratified according to participating center, menopausal status pre- vs post-menopausal, and tumor hormone-receptor status triple-negative vs progesterone-receptor negative, HER negative, and estrogen-receptor ER positive. Patients are randomized to 1 of 2 treatment arms. 